T. Rowe Price Associates’s Otonomy, Inc. OTIC Stock Holding History

T. Rowe Price Associates’s Portfolio OTIC Stock Details OTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-61,400	Closed	-$128K	–	3073
2022 Q2	$128K	Hold	61,400	–	–	﹤0.01%	2712
2022 Q1	$147K	Hold	61,400	–	–	﹤0.01%	2778
2021 Q4	$128K	Hold	61,400	–	–	﹤0.01%	2840
2021 Q3	$118K	Buy	61,400 +20,000	+48%	+$33.9K	﹤0.01%	2817
2021 Q2	$92K	Buy	41,400 +19,700	+91%	+$45.5K	﹤0.01%	2857
2021 Q1	$55K	Hold	21,700	–	–	﹤0.01%	2821
2020 Q4	$140K	Buy	+21,700	New	+$98.6K	﹤0.01%	2599
2020 Q3	–	Sell	-18,700	Closed	-$68K	–	2641
2020 Q2	$68K	Hold	18,700	–	–	﹤0.01%	2447
2020 Q1	$37K	Hold	18,700	–	–	﹤0.01%	2471
2019 Q4	$72K	Hold	18,700	–	–	﹤0.01%	2478
2019 Q3	$45K	Hold	18,700	–	–	﹤0.01%	2494
2019 Q2	$51K	Hold	18,700	–	–	﹤0.01%	2515
2019 Q1	$49K	Hold	18,700	–	–	﹤0.01%	2504
2018 Q4	$35K	Hold	18,700	–	–	﹤0.01%	2538
2018 Q3	$51K	Hold	18,700	–	–	﹤0.01%	2566
2018 Q2	$72K	Sell	18,700 -134	-0.7%	-$558	﹤0.01%	2549
2018 Q1	$79K	Buy	18,834 +55	+0.3%	+$300	﹤0.01%	2515
2017 Q4	$104K	Buy	+18,779	New	+$81.5K	﹤0.01%	2503
2017 Q3	–	Sell	-777,237	Closed	-$14.7M	–	2594
2017 Q2	$14.7M	Buy	+777,237	New	+$10.8M	﹤0.01%	1250
2017 Q1	–	Sell	-296,662	Closed	-$4.72M	–	2605
2016 Q4	$4.72M	Sell	296,662 -105,465	-26%	-$1.77M	﹤0.01%	1432
2016 Q3	$7.32M	Sell	402,127 -873	-0.2%	-$14.3K	﹤0.01%	1370
2016 Q2	$6.4M	Sell	403,000 -900	-0.2%	-$13.4K	﹤0.01%	1363
2016 Q1	$6.03M	Buy	+403,900	New	+$6.34M	﹤0.01%	1365
2015 Q2	–	Sell	-131,638	Closed	-$4.66M	–	2566
2015 Q1	$4.66M	Sell	131,638 -143,774	-52%	-$4.92M	﹤0.01%	1480
2014 Q4	$9.18M	Sell	275,412 -245,688	-47%	-$6.58M	﹤0.01%	1346
2014 Q3	$12.5M	Buy	+521,100	New	+$10.3M	﹤0.01%	1251

Other funds holding OTIC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

T. Rowe Price Associates's OTIC Position: Q3 2022 in Review

T. Rowe Price Associates sold out of Otonomy, Inc. (OTIC) in Q3 2022, closing a stake of 61,400 shares — an estimated $128K sold.

T. Rowe Price Associates first reported a position in OTIC in Q3 2014 and held it in 26 quarters. The position peaked at $14.7M in Q2 2017. 40 funds tracked by Wall St. Rank hold OTIC as of Q3 2022.

T. Rowe Price Associates reported no remaining Otonomy, Inc. position as of Q3 2022 after selling out during the quarter.
T. Rowe Price Associates sold 61,400 Otonomy, Inc. shares in Q3 2022, an estimated $128K.
T. Rowe Price Associates first reported a position in Otonomy, Inc. in Q3 2014 and held it in 26 quarters.
T. Rowe Price Associates's Otonomy, Inc. position peaked at $14.7M in Q2 2017.
40 funds tracked by Wall St. Rank held Otonomy, Inc. as of Q3 2022.

Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.